Copyright © 1998 by the European Society of Cardiology.
Incidence, outcome and prediction of early clinical events following percutaneous transluminal coronary angioplasty
A comparison between treatment with reviparin and unfractionated heparin/placebo (results of a substudy of the REDUCE Trial)
a Department of Cardiology, Tübingen University, Tübingen, Germany
b on behalf of the REDUCE Study Group
accepted February 25, 1998
Background Unfractionated heparin and its low molecular weight fragments possess antithrombotic properties, properties that are routinely exploited in coronary angioplasty (PTCA).
Objectives In the setting of the REDUCE trial, a randomized, double-blind, multicentre trial, the occurrence of acute or early clinical events was compared in patients treated with either unfractionated heparin/placebo or low molecular weight heparin (reviparin).
Methods and results Six hundred and twelve patients with native coronary artery obstructions randomized between unfractionated heparin/placebo and reviparin, were analysed. Baseline characteristics were similar in both groups. Using the intention-to-treat analysis, major acute or early events (myocardial infarction, re-PTCA, bypass surgery, death) occurred in 42 patients (7%), 29 in the control group and 13 in the treatment group (P=0·027). In order to develop a predictive model for the risk of early events following coronary balloon angioplasty, clinical as well as pre-PTCA and procedural characteristics were analysed. Thrombi at the treated lesion site (P=0·02), dissection (P<0·001), lesion type B2and C according to the NHLBI classification (P<0·001), diameter stenosis >50% post-PTCA (P<0·001), and length of stenosis >20mm (P=0·005) were significantly associated with the occurrence of acute events. By multiple logistic regression analysis, in which these variables and the treatment regimen were entered, dissection (P=0·042), diameter stenosis >50% (P<0·028) and lesion type B2and C (P=0·017) were found to be independently predictive of early adverse events. Bleeding complications were similar in the two treatment groups.
Conclusions Reviparin, given in a very early stage of vascular injury, compares favourably with unfractionated heparin/placebo, by reducing abrupt closure and acute-phase adverse outcome following PTCA. With respect to the evaluated risk factors for acute events, the positive effect of reviparin on early adverse outcome after PTCA may be due to improved antithrombotic properties as compared to unfractionated heparin.
Key Words: Clinical trials • coronary angioplasty • early acute events
f1 Correspondence: Melitta B. Preisack, M.D., Department of Cardiology, Schillerstr. 6a, 76726 Germersheim, Germany.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. A. Harrington, R. C. Becker, C. P. Cannon, D. Gutterman, A. M. Lincoff, J. J. Popma, G. Steg, G. H. Guyatt, and S. G. Goodman Antithrombotic Therapy for Non-ST-Segment Elevation Acute Coronary Syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 670S - 707S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. G. Steg and J.-M. Juliard Enoxaparin in non-ST segment elevation acute coronary syndromes: duration of therapy is essential to benefit Eur. Heart J., October 1, 2004; 25(19): 1667 - 1669. [Full Text] [PDF]
|
|
|
|
|
|
J. J. Popma, P. Berger, E. M. Ohman, R. A. Harrington, C. Grines, and J. I. Weitz Antithrombotic Therapy During Percutaneous Coronary Intervention: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 576S - 599S. [Abstract] [Full Text] [PDF]
|
|